Acute Sprint Interval Exercise Induces a Greater FGF-21 Response in Comparison to Work-Matched Continuous Exercise by Segsworth, Blair M
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
8-26-2015 12:00 AM 
Acute Sprint Interval Exercise Induces a Greater FGF-21 Response 
in Comparison to Work-Matched Continuous Exercise 
Blair M. Segsworth 
The University of Western Ontario 
Supervisor 
Dr. Peter Lemon 
The University of Western Ontario 
Graduate Program in Kinesiology 
A thesis submitted in partial fulfillment of the requirements for the degree in Master of Science 
© Blair M. Segsworth 2015 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
Recommended Citation 
Segsworth, Blair M., "Acute Sprint Interval Exercise Induces a Greater FGF-21 Response in Comparison to 
Work-Matched Continuous Exercise" (2015). Electronic Thesis and Dissertation Repository. 3254. 
https://ir.lib.uwo.ca/etd/3254 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
ACUTE SPRINT INTERVAL EXERCISE INDUCES A GREATER FGF-21 
RESPONSE IN COMPARISON TO WORK-MATCHED CONTINUOUS EXERCISE 
 
(Thesis format: Monograph) 
 
 
 
by 
 
 
 
Blair Mackay Segsworth  
 
 
 
 
Graduate Program in Kinesiology 
 
 
 
 
A thesis submitted in partial fulfillment 
of the requirements for the degree of  
Master of Science 
 
 
 
 
The School of Graduate and Postdoctoral Studies 
The University of Western Ontario 
London, Ontario, Canada 
 
 
 
 
© Blair Mackay Segsworth 2015 
 
 ii 
 
 
Abstract 
Sprint interval training (SIT) has been associated with substantial reductions in body 
fat. Recent evidence suggests that myokines (small protein compounds produced in 
muscle) may promote the fat loss with SIT. The purpose of this project was to 
compare the plasma accumulation of three myokines (IL-15, Irisin and FGF-21) with 
sprint interval exercise (SIE) vs work-matched continuous exercise (CE). Nine male 
subjects completed an acute SIE session consisting of four-30 second sprints and a 
work-matched CE session. Both exercise sessions were completed on an 
electromagnetically braked cycle ergometer. Blood samples were collected before 
and at 5, 30, 90, and 180 min post exercise to determine any changes in plasma 
myokine concentration. Plasma FGF-21 was increased at five (P=0.04) and 30 
(P<0.001) min with SIE vs baseline and was increased at 30 min (P=0.03) when 
compared to CE. Neither Il-15 nor Irisin were altered significantly although there 
were some methodology concerns and intersubject variability was substantial so a 
Type II Error might have occurred.  These findings suggest that exercise intensity is 
a key determinant of plasma FGF-21 accumulation and that FGF-21 may serve as a 
surrogate measure for both sympathetic activation and exercise-induced lipolysis. 
Keywords 
Irisin, Fibroblast Growth Factor-21, Interleukin-15, Myokines, fat loss  
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1 Introduction 
The current state of global health is at a crossroads between improvements in 
longevity and infant survival and the looming crisis associated with the rising 
rates of obesity. At this juncture, about 937 million people worldwide are 
considered to be overweight and ~396 million considered obese. Further, these 
numbers are projected to grow so that by the year 2030, it is expected that a 
staggering 1.12 billion people will be obese (Kelly et al., 2008). Many 
pharmacological interventions have been developed to battle this issue and its 
comorbidities such as hypertension, dyslipidemia and diabetes; however, it may 
be that the universal remedy to the obesity epidemic could simply involve 
consistent physical activity. For example, regular exercise has been shown 
previously to prevent excessive mass gain and even promote fat losses (up to 
386 cubic centimetres of adipose tissue) in obese adults over an 8-wk period 
(Keating et al., 2015). Unfortunately, regardless of these benefits, many people 
are unable to maintain physically active lifestyles, citing the lack of time as a 
major reason for ineffective quantities of exercise (Stutts, 2002). A possible 
solution to this issue is the use of sprint interval training (SIT) which results in 
significant fat loss and very brief time commitments (Hazell et al., 2014; 
MacPherson et al., 2010). 
Typically, sprint interval exercise (SIE) consists of four-six bouts of “all-out” 
intensity sprinting with each bout of sprints separated by a four min rest interval, 
often performed on a cycle ergometer (Burgomaster et al., 2005) but any 
exercise mode appears to work. As little as three min of “all-out” sprinting per 
week has been shown to increase activity of oxidative enzymes such as citrate 
synthase, cytochrome oxidase IV and β-hydroxy acyl CoA dehydrogenase as 
well as decreasing average 24-h blood glucose (Gillen et al., 2014). These trends 
in glucose homeostasis also apply to clinical populations as similar exercise 
modalities have caused reduced time spent with hyperglycemia both at rest and 
post-prandial (Gillen et al., 2012). Further, regular SIE can cause significant 
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improvements in body composition causing a decrease in fat mass and waist 
circumference by 8% and 3.5%, respectively, while increasing lean mass by 
1.5% over a 6 wk training period (Hazell at al., 2014). In terms of oxygen 
consumption, just two min of SIE induces similar 24-h oxygen consumption as 30 
min of continuous aerobic exercise (CE), despite SIE requiring 150% less in VO2 
load during the actual exercise (Hazell et al., 2012). These findings indicate a 
significant contribution to 24-h oxygen consumption due to an anaerobic exercise 
component and/or a residual change in post exercise metabolism. This resulting 
prolonged change in metabolism (increased baseline energy expenditure and/or 
elevated fat catabolism) may explain some of the fat losses often observed with 
SIT. 
When compared to moderate intensity CE training, meta-analyses demonstrate 
that SIT produces similar 8% increases in VO2max (Gist et al., 2013) due primarily 
to an increase in mitochondrial density and the upregulation of oxidative 
enzymes such as cytochrome oxidase IV and β-hydroxy acyl CoA 
dehydrogenase (Sloth et al., 2013). Interestingly, SIT promotes similar changes 
in exercise capacity vs CE with exercise volumes of ~10% and total exercise time 
of ~21% (Gibala et al., 2006). Moreover and importantly, interval training, even 
intense SIT has also been associated with higher ratings of perceived pleasure 
when compared to CE (Bartlett et al., 2011).  
Many of the peripheral adaptations to SIT are due to increased mitochondrial 
content that occurs along with improved oxidative capacity (Jacobs et al., 2013, 
Scalzo et al., 2014). On a molecular level, it is thought that the increased 
mitochondrial biogenesis is caused by the phosphorylation of p38 MAPK and 
AMPK which promotes an increase in PGC-1α mRNA content (Gibala et al., 
2008). This connection is critical as PGC-1α is known to be the master regulator 
of mitochondrial biogenesis as well as many of the oxidative genes linked to 
mitochondrial function (Wu et al., 1999). Although there is an established link 
between SIT and the induction of oxidative adaptations, the precise mechanism 
regulating these changes has not been elucidated fully.  However, the 
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biochemical signaling process responsible for the adaptations appears to be 
more powerful because these metabolic changes are induced by substantially 
less total work volume and time. 
A new theoretical model describing the function of muscle has also been 
described concurrently with the development of SIE as an effective exercise 
mode. Like adipose tissue, skeletal muscle is now known to act much like an 
endocrine organ, capable of secreting several hormonal signals to communicate 
with a number of other body tissues (IIzuka et al., 2014, Pedersen and Febbraio, 
2013). Rather than communicating via fat-soluble hormones, skeletal muscle 
utilizes contraction-induced cytokines to implement functional changes 
throughout the body (Pedersen and Febbraio, 2013). These have become known 
as myokines because the tissue of origin for these cytokines is muscle and, as of 
2014, there are at least 69 identified myokines within the secretome of muscle 
(Catoire et al., 2014). One of the most well characterized myokines is IL-6, 
traditionally a pro-inflammatory cytokine, it is increased chronically in the obese 
(Pal et al., 2014). IL-6 is also elevated acutely following exercise and improves 
insulin and glucose sensitivity through the up-regulation of glucagon-like peptide-
1 (Pal et al., 2014). Although much effort has been directed to the study of IL-6, a 
new subgroup of myokines has been identified as perhaps playing a role in how 
exercise promotes fat loss. 
Irisin, Fibroblast Growth Factor-21 (FGF-21) and Interleukin-15 (IL-15) are three 
novel myokines that have been implicated with fat metabolism, oxidation and 
phenotypical changes. Specifically, Irisin promotes a brown/beige adipose 
phenotype, in which an induction of gene related mitochondrial biogenesis (PGC-
1α, UCP-1, GLUT-4) has been reported (Vaughn et al., 2014, Huh et al., 2014). 
Further, in conjunction with FGF-21, Irisin increases non-shivering 
thermogenesis in beige/brown adipose via uncoupling of the electron transport 
chain (Lee et al., 2014). Interestingly, non-shivering thermogenesis induction by 
Irisin and FGF-21 are similar between both cold environmental conditions and 
exercise, with greater plasma concentrations of the induced myokines found 
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post-exercise (Lee et al., 2014). With respect to phenotype, beige/brown adipose 
is advantageous because 60 g of brown adipose is capable of metabolizing ~4 kg 
of white adipose over the course of a year (Virtanen et al., 2009). Moreover, 
FGF-21 may also provide a substantial body fat reduction benefit in that it is 
capable of increasing glucose uptake (Kharitonenkov et al., 2005), the 
deacetylation and activation of PGC-1α (Fu et al., 2009), as well as help 
coordinate the metabolic response to exercise-induced lipolysis (Lee et al., 2013, 
Cuevas-Ramos et al., 2012).  
Traditionally, IL-15 has been viewed as an anabolic myokine, capable of inducing 
the accretion of myosin heavy chain proteins within human muscle cells 
(Furmanczyk and Quinn, 2003) as well as assisting in lipid oxidation and storage.  
The treatment of adipocytes with IL-15 can reduce lipid deposition by 50% 
(Quinn et al., 2005), enhance the expression of PGC-1α in muscle cells, and 
increase total mitochondrial volume (O’Connell and Pistilli, 2015). Interestingly, 
mice over-expressing IL-15 have been shown to have lower resting RER, up-
regulation of PGC-1α, and increased oxidative muscle fibre content (Quinn et al., 
2013). Considering the role of these myokines in producing a more oxidative (β-
oxidation) phenotype, it is imperative to discern their role and induction post-
exercise. 
Recently, Irisin, FGF-21 and IL-15 have been studied with some types of 
exercise. For example, Irisin with both resistance (strength) and aerobic 
(endurance) exercise paradigms and appears to respond to intensity of exercise 
in a dose-dependent manner (Huh et al., 2012, Huh et al., 2014). Apparently 
acute sprint exercise causes Irisin to accumulate at a concentration 15% greater 
than an endurance bout (Huh et al., 2014); however, in this study the exercise 
conditions were not matched for total work output so these data may be 
confounded. FGF-21 has been reported to increase one h after an acute bout of 
modest aerobic exercise (50% of VO2max), yet the effect of acute sprinting on the 
secretion of FGF-21 has not been researched extensively (Kim et al., 2013). In 
this regard, FGF-21 has only been studied in a SIT regimen consisting of nine 
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sessions of four-eight 30s sprinting bouts on a cycle ergometer (Scalzo et al., 
2014). Similarly, the relationship between exercise and the induction of IL-15 in 
humans has not been well documented but significant increases in circulating IL-
15 after with moderate intensity (50-70% of VO2max) cycling or running have been 
reported (Christiansen et al., 2013, Tamura et al., 2011). There have been no 
studies profiling the acute effect of SIE on the secretion of IL-15. 
Therefore, the aim of this thesis was to conduct a work-matched comparison 
(per-joule basis) of Irisin, FGF-21 and IL-15 between acute SIE and CE to 
determine which exercise modality induces the greatest myokine response. In 
essence this will determine the role of exercise intensity- defined as a percentage 
of VO2max- in the accumulation of plasma myokines. It was hypothesized that SIE 
would promote the greatest increase in plasma Irisin, FGF-21 and IL-15 and 
thereby perhaps be the mechanistic link between SIE and its noted ability to 
stimulate both oxidative adjustments to exercise and the resulting positive 
changes in body composition.     
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2 Literature Review 
2.1 Sprint Interval Exercise in Humans 
Typically, sprint interval exercise (SIE) is defined as four-six, 30 sec “all-out” 
sprints separated by a four min recovery interval that may be either active or 
passive (Burgomaster et al., 2005). These sprints are often repeat Wingate tests, 
i.e., 30 sec sprints on a cycle ergometer at a resistance of eight-10% of body 
mass (Burgomaster et al., 2005, Hazell et al., 2012). Two min of SIE has been 
reported to induce a similar oxygen consumption (VO2) over a 24-h period as a 
30-min continuous, moderate intensity endurance bout of exercise (CE) (Hazell 
et al., 2012). In the aforementioned study, it is interesting to note that, although 
the oxygen consumption was significantly less during the SIE session, the 24-h 
consumption was not different vs the 30-min endurance exercise, indicating that 
SIE may cause biochemical or physiological changes that induce an extended 
increased oxygen consumption post exercise. Further, in both men and women, 
SIE has been shown to result in substantial body fat loss despite very little 
training time. In women, SlT on a self-propelled treadmill three times per wk for 
six wk reduced fat mass by 8%, waist circumference by 3.5% and also increased 
maximal oxygen consumption by 8.7% (Hazell et al., 2014). During this training, it 
is noteworthy that the participants did not appear to change their diet 
significantly. In men, a similar training protocol involving a progressive increase 
in sprints (from four to six over six wk) induced a 3kg loss of body fat 
(MacPherson et al., 2010). Further, in a subsequent study, acute SIE had little 
effect on energy intake despite increased appetite and energy expenditure 
(Beaulieu et al., 2014).  These observations indicate that changes in food intake 
are not the main factor responsible for the improved body composition.  
Another study with untrained, middle aged men who underwent SIT, consisting of 
four-six bouts of 30 sec all-out sprints for a total of just six training sessions 
observed an increase in VO2 peak of 6%, as well as an increase in muscle 
glucose uptake (Eskelinen et al., 2015). Interestingly, the effect of increased 
glucose uptake was isolated to the quadriceps femoris muscles. When compared 
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to other muscle groups the changes in glucose and fatty acid uptake during 
exercise was only present within the quadriceps, indicating a local effect of the 
SIT perhaps induced by a form of autocrine/paracrine signaling. All four muscles 
of the quadriceps responded to SIT, while in comparison, only the vastus lateralis 
and vastus medialis responded to moderate intensity exercise (Eskelinen et al., 
2015).  
Metabolically, acute SIE has resulted in increased phosphorylation of AMPK and 
p38MAPK immediately after four bouts of 30-sec sprints (Gibala et al., 2008). In 
the same study there was also a two-fold up-regulation of PGC-1α mRNA at 
three h into recovery. Since SIE was capable of inducing an increase in PGC-1α 
and the aforementioned regulators of oxidative metabolism, the authors 
concluded that SIE was also capable of increasing mitochondrial content. 
Therefore these findings contribute further to the idea that SIE is capable of 
inducing similar increases in mitochondrial content and metabolic remodeling to 
that caused by traditional endurance training. To support these findings, electron 
transport chain protein cytochrome c oxidase, a marker for mitochondrial content, 
has been shown to increase with SIT (Gibala et al, 2006). Another study using 60 
sec intervals have found increases in cytochrome c oxidase content, a 
concurrent 7.9% increase in VO2max, and a 5.1% increase in mean power output 
(Jacobs et al., 2013). In a similar study, Perry et al. (2008) observed an 18% 
increase in cytochrome c, increases in B-hydroxyacyl-CoA dehydrogenase, and 
GLUT4 content within muscle after the completion of a high intensity interval 
training regime consisting of 10 x four min intervals at 90% VO2max, three times 
per wk, for six wk. Further, during 60% VO2 peak exercise there was a 60% 
increase in fat oxidation after six wk of training when compared to pre-training 
values at the same intensity. These findings indicate that high-intensity spectrum 
training such as SIT may induce long-term changes in the efficacy of energy 
substrate utilization during exercise. 
In a meta-analysis of the cardiovascular adaptations to SIT, Gist et al. (2013) 
found that SIT and moderate-intensity continuous interval training were similar in 
   8 
 
their relative ability to increase VO2max. However, there was a 20% reduction in 
the time required to accomplish these endpoints with SIT. These findings are 
supported by another meta-analysis, which found that VO2max increases in a 
range of four-13% with SIT over two-eight wk (Sloth et al., 2013). It was also 
shown that there are similar changes in exercise performance, glycemic control 
and insulin sensitivity with SIT when compared to more traditional high-volume 
training regimes (Sloth et al., 2013). These findings suggest that there may be 
separate biochemical pathways or an amplification of factors that are inherent 
within SIT, making it more efficient at inducing the benefits associated with 
exercise. 
The effect of SIT on the secretion of plasma cytokines/myokines is also 
important. As outlined above, SIT has been observed to decrease the resting 
plasma concentrations of FGF-21, after nine sessions of four-eight, 30 sec bouts 
of all out sprints (Scalzo et al., 2014). Under the same training program, Irisin has 
a sexually dimorphic response, increasing in women after SIT and decreasing in 
men (Scalzo et al., 2014), while SIE increases plasma Irisin acutely (Huh et al., 
2014). Outside of the aforementioned myokines, SIE has also been reported to 
have an effect on a wide variety of plasma inflammatory markers. Meckel et al. 
(2011) showed that SIE increases both pro- and anti-inflammatory factors such 
as Il-1 and IL-6 immediately after a series of successive sprints of 100-400 
metres, while IL-6 remained elevated one h into recovery. These data suggest 
that along with other cyto/myokines, there may be a global response to sprint 
exercise, rather than the production of a single subset of secreted myokines. On 
the other hand, SIT has also been shown to have no effect on resting plasma 
myokines IL-6, IL-10 and C-reactive protein after 2 wk of thrice weekly bouts of 
four-six 30s sprints (Hovanloo et al., 2013). It is difficult to determine the long 
term effects of SIT on plasma protein concentrations because there are such 
divergent results in the effect of SIT and plasma inflammation markers. Although 
there are a limited number of studies presented focusing on the effect of SIE on 
myokine concentrations, it is apparent that there is a gap within the literature and 
this must be addressed in the context of both SIE and SIT. 
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In conclusion, SIE is a powerful exercise modality that is capable of inducing 
similar benefits as traditional endurance exercise with far less total energy and 
time commitment. It appears that SIE mediates these functions though the up-
regulation of mitochondrial transcription factors as well as supporting 
mitochondrial biogenesis and growth. However, is it unclear by which 
mechanisms that these processes occur. The effect of SIE on plasma 
inflammatory markers and myokines has not been studied systematically in the 
literature and thus requires attention. 
2.2 Irisin 
In the groundbreaking study first describing Irisin, Boström et al. (2012) found 
that a product of the proteolytic cleavage of the skeletal muscle integral 
membrane protein fibronectin type 3 domain containing 5 (FNDC5) was secreted 
into the bloodstream during exercise. Given the name Irisin for the Greek 
messenger goddess Iris, this myokine circulates as a 112-amino acid protein 
(Wrann et al., 2013). The exact process by which FNDC5 is cleaved and 
released into the bloodstream remains unclear, but it is postulated to be similar in 
fashion to other transmembrane polypeptide hormones such as Transforming 
Growth Factor-α (Boström et al., 2012). Previous biochemical studies have 
shown that while Irisin is a 16 stranded β-sheet dimer of two cleaved FNDC5 
proteins for intercellular signaling, there is also a dimerization of FNDC5 
endodomains for intracellular cell signaling (Schumacher et al, 2013). This leads 
to the possibility that activation of the Irisin receptor can induce both endocrine 
functions within a whole organism and autocrine functions on skeletal muscle. 
Irisin is thought to mediate its activity through the master regulator of 
mitochondrial biogenesis, PGC-1α, and morphogenic changes due to Irisin are 
believed to be mediated by changes in ERK and p38 MAPK regulation (Zhang et 
al., 2014). 
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2.2.1 Cell Studies 
Irisin is believed to be sourced directly from skeletal muscle cells, contributing to 
72% of all circulating Irisin (Boström et al., 2012; Roca-Rivada et al., 2013). 
However, this assumption may be subject to change. Using 
immunohistochemistry to stain for Irisin within different cell cultures taken from 
human cadaveric tissue, Aydin et al. (2014), found that the main source of Irisin 
is not from skeletal muscle, but rather from the nerve sheaths that spread within 
muscle tissue with smaller other contributions derived from the perimysium and 
epimysium. Among the most responsive human tissues were the testis, 
pancreas, liver, spleen, brain, stomach and cardiac tissues. By following the 
staining patterns of Irisin and their tissue relationships, Aydin et al. (2014) 
concluded that Irisin may play an important role in hypothalamic-pituitary-gonadal 
axis. 
Further, Irisin has been shown the be produced and secreted into cell media by 
both human and C2C12 myocytes at rest, yet electrical pulse stimulation has 
been shown to cause no significant increase in FNDC5 gene expression 
(Raschke et al., 2013). Considering that Irisin has been shown to be related 
inversely to PCr and ATP concentrations within muscle tissue (Huh et al., 2012) 
and its downstream effects can be nullified by AMPK inhibitor, Compound C (Huh 
et al., 2014), it may be that the secretion of Irisin is dependent on the accretion of 
exercise-induced metabolites, rather than by simple muscular contraction.  
Tissues treated with Irisin have shown a wide range of effects. Human muscle 
cells taken from biopsies of obese individuals treated with Irisin produced 
increased IGF-1 and decreased myostatin mRNA expression (Huh et al., 2014). 
In adipose cells derived from the same human donors, both physiological and 
below-normal concentrations of Irisin inhibited lipid accumulation and significantly 
inhibited fatty acid synthase. Moreover, after eight days of Irisin treatment, mRNA 
of genes for thermogenic programs such as cell death-inducing DFFA-like 
effector A (CIDEA) and uncoupling protein 1 (UCP-1) increased, as well as 
markers of mitochondrial biogenesis, PGC-1α and TFAM (Huh et al., 2014). In 
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the same study, adipose triglyceride lipase was also up regulated, indicating that 
with the increased expression of UCP1, there is also an increased use of fat 
substrate for oxidation and heat production. As a final measure, Irisin treatment 
inhibited adipocyte differentiation and maturation in human and mouse pre-
adipocytes.  
As suggested by biochemical characteristics, it has been shown through in-vitro 
studies that Irisin exerts an autocrine effect on skeletal muscle. For example, 
C2C12 myocytes treated with Irisin have an increase in expression of genes 
related to mitochondrial biogenesis including PGC-1α, NRF-1, TFAM, GLUT4, 
UCP3 and Irisin (Vaughan et al., 2014). The noted increase in Irisin gene 
expression suggests that circulating Irisin exerts an autocrine, positive feedback 
loop back on skeletal muscle. The Irisin-treated myocytes also had a greater 
amount of global mitochondrial organelle content and expressed a greater total 
carbohydrate oxidation and decreased lactate production (Vaughan et al., 2014). 
Combined with its positive feedback loop and increased mitochondrial 
biogenesis, it appears that Irisin exerts a shift to an oxidative phenotype within 
skeletal muscle and adipose tissue. It is important that the secreted portion of 
Irisin is also highly conserved within all mammalian species; mouse and human 
Irisin are 100% identical (Bostrom et al., 2012). Recently, it has been shown that 
both shivering and exercise cause a similar secretion of Irisin, although 
marginally greater plasma concentrations are achieved through exercise (Lee et 
al., 2014). Combined with another myokine, FGF21; Irisin induces the browning 
of adipose as well as non-shivering thermogenesis in response to lower body 
temperature in human subjects (Lee et al., 2014). From these experimental data 
and the conservation of Irisin structure through mammals, it is believed that Irisin 
is a remnant of evolutionary homology to cold changes within the environment. 
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2.2.2 Animal Studies 
In mice, submaximal treadmill exercise to volitional fatigue induces a two fold 
increase in plasma Irisin concentration, while free running and control mice 
showed no increase in plasma Irisin (Brenmoehl et al., 2014). There were also 
higher concentrations of Irisin within homogenates of femoral muscles, when 
compared to those of crus (forelimb) muscles in mice. Irisin was also not 
correlated with the running distance of the either the voluntary free-wheel running 
or the treadmill test, suggesting the determinant of the Irisin response may be 
exercise intensity not duration (Brenmoehl et al., 2014). Through 
immunohistochemical staining, it was also shown that Irisin was localized around 
muscle cell membranes and intercellular spaces. This corresponds with the 
findings of Aydin et al. (2014) who suggested Irisin might be a product of the 
nerve sheaths permeating through muscle tissue with smaller contributions also 
originating from the epimysium and perimysium. Of the various muscle types, 
slow/oxidative fibres secrete ~40% more Irisin than glycolytic fibres (Roca-Rivada 
et al., 2013). Further, in a separate study, three wk of endurance training reduced 
the concentration of Irisin in plasma, suggesting a role of muscle and exercise 
training in the down-regulation of Irisin signaling (Roca-Rivada et al., 2013).  
Animal studies have also shown that adipose tissue may play a role in Irisin 
homeostasis. Roca-Rivada et al. (2013), suggested that a secreted form of 
FNDC5 in rats is also produced by adipose tissues and that obese rats over-
secrete this protein in adipose. These findings may illustrate a feedback 
mechanism between muscle and adipose for Irisin and further, that there may be 
an Irisin resistance during obesity and other metabolic disorders. Comparing 
adipose types, subcutaneous adipose secretes 40% more FNDC5/Irisin 
compared to visceral fat. Contrary to these findings, Roberts et al. (2013) found 
that circulating Irisin tended to be lower in obese/diabetic prone Otsuka Long-
Evans Tukushima Fatty (OELTF) rats. Triceps brachii biopsies showed that 
FNDC5 and PGC-1α mRNA were found to be 50% and 40% less in OLETF rats, 
respectively and were correlated with body composition. Total body fat and 
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plasma Leptin concentrations are associated positively with greater skeletal 
muscle FNDC5 mRNA expression. It is speculated that Leptin may be a key in 
the cross talk between muscle and fat because Leptin increases PGC-1α through 
AMPK mediated signaling.  Therefore, Irisin may serve as a compensatory 
mechanism to stimulate thermogenesis and increase fat loss in the obese state 
(Roberts et al., 2013). 
A unique and interesting role of Irisin may be located in the central nervous 
system. Wrann et al. (2013) have proposed the link between exercise and brain 
BDNF production to be Irisin and the FNDC5 receptor. Via endurance exercise, 
activation of FNDC5 within the hippocampus of mice was observed to cause an 
increase in BDNF mRNA. It is believed that the effects of FNDC5 on BDNF 
transcription is mediated through a complex formed by PGC-1α and Estrogen 
Related Receptor-α (ERRα) as both PGC-1α and ERRα knockout mice had 
dramatically reduced FNDC5 activity (Wrann et al., 2013). Hippocampal 
expression of BDNF was also shown to have a negative feedback effect on 
FNDC5 activity within the brain, indicating a homeostatic loop between FNDC5 
and BDNF. The most significant finding from Wrann et al. (2013), is that the 
peripheral delivery of FNDC5 to the liver via adenoviral vectors caused an 
increase in the central expression of BDNF. This is a clear indication that a 
secreted factor influences the central activity of FNDC5 and implies a 
communication axis between exercising muscle, the liver and the brain; however, 
it has yet to be determined if the main signaling molecule is Irisin or another 
cleavage product from muscle FNDC5 (Wrann et al., 2013). 
As promising as the animal studies surrounding Irisin may be, it is often difficult 
to translate research from rodent studies to humans. Raschke et al. (2013) 
outlined the fact that there is a mutation in a start codon of the FNDC5 gene 
between rodents and humans. This mutated form of FNDC5 has low translation 
efficiency in humans and only resulted in 1% of full length FNDC5 protein, when 
compared to rodents. Raschke et al. (2013) also found that FNDC5 gene 
expression was not increased during in-vitro electrical pulse stimulation of 
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primary skeletal muscle cells. As previously stated, these data must be taken 
with some skepticism because electrical pulse stimulation is far from exercise 
and often does not result in the accretion of exercise metabolites. Many of these 
metabolites such as AMP and the subsequent activation of AMPK are implicated 
in the activation of FNDC5 gene pathways and secretion of Irisin into the 
bloodstream. 
2.2.3 Human Studies 
Many studies have profiled the existence of Irisin and its association with 
exercise. While studying the physiological variation in plasma Irisin, Anastasilakis 
et al. (2014), found that a diurnal rhythm of Irisin exists, with maximum plasma 
concentrations being reached at 2100h and minimums at 600h. Interestingly, this 
day-night rhythm is opposite of FGF-21 (Anastasilakis et al., 2014). It was 
suggested that the inverse relationship between plasma Irisin and FGF-21 
concentrations may be due to temperature, where Irisin plays a role in the 
formation of brown adipose tissue (Vaughn et al., 2014) and FGF-21 then 
activates that tissue for heat production during lower overnight temperatures as 
outlined by Anastasilakis et al. (2014) and Lee et al. (2014.  
Huh et al. (2012), using biceps circumference as a gauge, showed that muscle 
mass was the single greatest indicator of circulating plasma Irisin. Plasma Irisin 
is correlated positively with BMI and negatively correlated with age, insulin, and 
cholesterol within the blood. Subjects who had undergone bariatric surgery were 
observed to have a reduction in both total and lean body mass which coincided 
with a subsequent decrease in resting plasma Irisin when compared to pre-
surgery (Huh et al., 2012). It was also shown that a 7% reduction in body mass 
due to a hypocaloric diet also caused a reduction in plasma Irisin (De La Iglesia 
et al., 2014), suggesting a relationship between Irisin production and skeletal 
muscle. Young, male, athletes were found to have the highest resting plasma 
concentrations of Irisin (Huh et al.,  2012); however, when adjusted for lean body 
mass, females were found have even greater resting Irisin concentrations 
(Anastasilakis et al., 2014). In a separate study involving a population of 17 post-
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menopausal women, Swick, Orena, & O’Connor (2013) found that the subgroup 
of women who had daily energy expenditures greater than the predicted values 
of energy expenditure∙kg fat free mass-1 also had the greatest concentrations of 
resting plasma Irisin. From this information it was hypothesized that the 
increased energy expenditure may be due at least partially to the browning effect 
of Irisin on adipose tissues. 
With respect to Irisin, the effect of exercise and exercise intensity has been 
studied but remains controversial. Acutely, Irisin has been shown to increase 
within the blood in response to endurance exercise by about 20% (Anastasilakis 
et al., 2014). Sprint interval exercise has also been shown to induce an increase 
in plasma Irisin (Huh et al., 2012). For example, three sets of two, 80 metre 
sprints with 20 min of rest between sets induced an 18% increase in plasma 
Irisin, 30 min after exercise. In the same study, the increase in Irisin was 
correlated with the decrease in ATP and PCr, while having no relationship with 
ADP or pyruvate. The same sprint protocol was conducted three times per wk 
over an eight wk period and at the conclusion of the training the acute induction 
of Irisin immediately after the sprints Irisin was no longer significant. Interestingly, 
there was also no acute decrease in ATP, suggesting that Irisin may respond to 
ATP depletion and that the intensity of the sprint exercise was no longer great 
enough to induce an Irisin response (Huh et al., 2012). Plasma Irisin has also 
been observed to be elevated after acute static exercise performed on vibration 
platforms in untrained women (Huh et al., 2014). However, contrary to their 
previous findings, Huh et al. (2014) found that the acute Irisin response to 
exercise was maintained after nine wk of vibration training suggesting that 
vibration may be different than exercise per se. 
Huh et al. (2014) further described Irisin as being present in lower concentrations 
in both physically active and older individuals at rest, when compared to 
sedentary or young individuals. However, acute increases in plasma Irisin 
immediately after exercise were unrelated to fitness or age. In a comparison 
between five, 50 metre swimming sprints and a single 2,000 metre endurance 
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swim, Huh et al. (2014), found that Irisin was elevated in plasma by 30% 
immediately after and by 15% one h after the sprint condition, while the 
endurance group showed no significant change. As stated earlier, there was no 
interaction between fitness, age and the increase in plasma Irisin, thus the 
authors concluded that, regardless of baseline plasma Irisin, the response to 
acute exercise is similar (Huh et al., 2014). Moreover, similar plasma Irisin 
concentrations have been found with VO2max treadmill tests (34% increase in 
plasma Irisin) as with 10 min at 70% VO2max or 10 min at an absolute (75W) 
workloads (Daskaloupolou et al., 2014). Using 90 min of continuous treadmill 
running, Kraemer et al. (2014) reported that plasma Irisin was only significantly 
different from rest at 54 min of exercise rather than at the completion of the 90 
min exercise bout. These findings indicate that the Irisin response of muscle may 
only be limited to a small window of activity after the initial onset of exercise. 
Lastly, Tsuchiya et al. (2014) showed that 20 min of high intensity exercise at 
80% VO2max produced plasma Irisin concentrations greater than pre-exercise 
values at six and 19h after exercise by 18% and 23%, respectively. In contrast, 
40 min of low intensity exercise (40% VO2 max) caused no increase from pre-
exercise values. Further, low intensity exercise produced a decrease in plasma 
Irisin. The findings of Tsuchiya et al., (2014) suggest that the Irisin response from 
muscle may, although unlikely, be delayed in nature because there was no Irisin 
response until six hours post-exercise.  
The Irisin response to both endurance and sprint training is not nearly as clear as 
the acute effect of exercise. In the original paper outlining the existence of Irisin, 
Boström et al. (2012) found that endurance training (10 wk of four-five sessions 
of 20-35 min cycling at 65% VO2max per wk) promoted a twofold increase in 
plasma Irisin concentrations in humans at rest. SIT has been shown to decrease 
resting plasma Irisin in males, while increasing resting plasma Irisin in females 
Scalzo et al. (2014). Scalzo et al. (2014) also determined that the secretion of 
Irisin into the plasma is unaffected by the sympathetic stimulation associated with 
exercise as there were no changes in plasma Irisin due to either inhibition by 
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clonidine (a central acting adrenergic agonist), or by hypoxia- induced 
sympathetic activation. 
In terms of resistance exercise, 12 wk of progressive resistance training in 
untrained women had no effect on FNDC5 expression or serum Irisin (Ellefsen et 
al., 2014). Further, it was found that FNDC5 expression was closely correlated to 
the proportion of aerobic muscle fibres pre-training, but this correlation 
disappeared post-training. In the untrained state, Irisin appeared to be correlated 
to both lean body mass and fat mass, yet in the trained state, was only related to 
fat mass (Ellefsen et al., 2014). These findings suggest that there may be a 
change in Irisin regulation within muscle due to strength training. 
 There is a great deal of controversy surrounding the existence of Irisin and its 
production as a result of exercise. Pekkala et al. (2013), have shown that there is 
an inconsistent Irisin response to resistance and low intensity endurance training. 
No differences in FNDC5 expression in muscle were found after 21 wk of aerobic 
or aerobic/resistance combined training; however, an acute high-intensity 
resistance bout increased PGC-1a mRNA expression four-fold in older men, 
while increasing FNDC5 mRNA expression 1.4 times in young men, reinforcing 
the notion that the function of FNDC5 and Irisin, if any, may only be acute in 
nature. Hecksteden et al. (2013) showed similar results indicating that there were 
no changes in resting Irisin after a 26 wk combined resistance and aerobic 
training program. Further, they also noted that there was an effect of storage time 
for Irisin, where longer time in freeze storage resulted in reduced Irisin 
concentrations as determined by ELISA. Hecksteden et al. (2013) found that at -
20°C, there was a degradation slope that was calculated to be 0.184 ng∙ml-1∙day-
1.  Using only gene chip analysis, (Timmons, Baar, Davidsen, & Atherton, 2012) 
showed that out of 200 subjects, an increase in FNDC5 expression was only 
evident in a small subgroup of highly active elderly subjects. After undergoing 
aerobic or resistance training protocols, there was no increase in FNDC5 
expression, while an increase in PGC-1α was consistent throughout all groups. 
These data allowed Timmons et al. (2012) to conclude that FNDC5 and Irisin are 
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perhaps non-existent in humans or, as claimed by (Raschke et al., 2013), a 
pseudo gene. In a rebuttal published in Nature, (Boström et al., 2012) responded 
to these issues, stating that gene chip analyses are not a robust quantitative 
measure and are more qualitative in design, limiting any conclusions based on 
the change in FNDC5 transcription. It must also be noted that the subjects for 
Timmons et al. (2012), had undergone endurance exercise training and the acute 
secretion of Irisin was not evaluated. From many of the studies reviewed, it 
appears that FNDC5 activation and the subsequent release of Irisin is acute in 
nature and that it may be the chronic exposure to the pulsatile release of Irisin 
during exercise that is the true mediator of any beneficial effects.  
Regardless of what controversy that may exist, it is safe to conclude that Irisin is 
indeed a myokine that is induced during exercise. It is likely that any secretion of 
Irisin is dependent on total muscle mass, but presents a dichotomy between men 
and women, where females appear to have greater resting concentrations and 
increase plasma Irisin as a response to exercise training. Irisin appears to be 
responsible for morphogenic changes within adipose tissue, being capable of 
inducing a brown/beige adipose phenotype. It is likely that the secretion of Irisin 
is dependent on the intensity of exercise as displayed by the studies featuring 
SIE; however, this concept requires further attention. 
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2.3 Fibroblast Growth Factor-21 
Discovered by Nishimura et al. (2000), Fibroblast Growth Factor-21 (FGF-21) 
was identified as a 210 amino acid protein and found to be expressed within the 
liver. The amino acid sequence of FGF-21 is almost entirely identical between 
mice and humans and relative to the other Fibroblast Growth Factors, is most 
similar to FGF-19 in structure. FGF-21 responds to starvation and stress within 
the liver. Unlike most FGF family members that have autrocrine or paracrine 
functions requiring heparin sulfate binding, FGF-21 is capable of exerting 
endocrine effects and is dependent on β-Klotho for receptor binding (Bae, Kim, & 
Park, 2014). Interestingly, β-Klotho is almost exclusively expressed within the 
liver, adipose tissue and pancreas, indicating that the endocrine target tissues of 
FGF-21 are most likely to be the pancreas and adipose tissue. 
2.3.1 Cell Studies 
Many cell studies have focused on the capabilities of FGF-21 as a signaling 
molecule as well as the nature of its regulation. Using Murine C2C12 myocytes, 
Ribas et al. (2012), showed that FGF-21 was induced upon the differentiation of 
myoblasts into myotubes. It was found that the transcription co-factor, MyoD, 
controls FGF21 mRNA expression as the overexpression of MyoD caused an 
induction of both FGF-21 mRNA and an increase in FGF-21 protein within the 
cell media (Ribas et al., 2012). Mitochondrial dysfunction induced by oligomycin- 
an inhibitor of complex II within the electron transport chain- also showed an 
increased amount of FGF-21 protein production. This response was blunted by 
the presence of reactive oxygen species scavenger Trolox, a soluble form of 
Vitamin E. These data implicate FGF-21 as a marker for mitochondrial 
dysfunction or stress. FGF-21 has been implicated as a possible avenue for the 
treatment of Metabolic Syndrome, as the treatment of FGF-21 in both mouse 
3T3-L1 adipocytes and human primary adipocytes causes an increase in glucose 
uptake (Kharitonenkov et al., 2005). 
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2.3.2 Animal Studies 
The relationship between energy homeostasis and FGF-21 has been thoroughly 
studied in both rats and mice. In conjunction with their evaluation of the effects of 
FGF-21 on adipocytes, Kharitonenkov et al. (2005), also showed that the 
therapeutic administration of FGF-21 was capable of reducing plasma 
triglycerides and blood glucose to normal concentrations in both leptin-deficient 
and diabetic-obese rats. Obesity is also implicated to be an FGF-21 resistant 
state as Fisher et al. (2010), showed that diet-induced obese rats had elevated 
resting plasma FGF-21 and that rats treated with FGF-21 have a reduced 
response to treatment as measured by the phosphorylation of ERK 1/2. It may be 
that this is caused by the up regulation of micro RNA-43a (miR-43a) (Fu et al., 
2014). MiR-34a was shown to be a key in the inhibitor of FGF-21 receptor 
components and may explain the FGF-21 resistance that is observed within the 
obese state. Downregulation of this micro RNA by the use of the anti-sense 
strand for miR-43a also showed improved lipid and glucose profiles and 
promoted the formation of brown and beige adipose tissue (Fu et al., 2014). In 
addition, Fu et al. (2014) also showed that FGF-21 is a key mechanism for the 
deacetylation and activation of the PGC-1α gene and its subsequent effects in 
promoting an oxidative phenotype through mitochondrial biogenesis. The authors 
concluded that FGF-21 may exert this effect through increasing the activity of the 
enzyme AMPK. 
FGF-21 has been reported to also be involved in the response to starvation and 
malnutrition. Kubicky et al. (2012), showed that with four wk of food restriction, 
wild type mice had decreased body mass and tibial growth when compared to 
FGF-21 knockout mice. The knockout mice showed normal growth patterns, but 
these differences from wild type were abrogated when they were treated with 
daily recombinant FGF-21. In the food restricted group, FGF-21 mRNA was up-
regulated in comparison to a group feeding ad libitum as well as a reduction in 
circulating growth hormone and growth hormone receptor protein at the tibial 
growth plate, indicating that FGF-21 reduces the functionality of growth hormone 
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during starvation (Kubicky et al., 2012). The authors concluded from these data 
that FGF-21 plays a causative role in reducing growth in malnutrition as an 
adaptive stress response. In addition to these findings, Laeger et al. (2014) found 
that circulating FGF-21 in rats and mice increased 10 fold while on a low-protein, 
isoenergetic diet when compared to controls. Protein restriction in humans also 
caused an increase in circulating FGF-21, inducing a 121% increase in 
circulating FGF-21 after 28 days on a low-protein diet. FGF-21 was found to be 
responsible for the behavioural adaptations to low-protein diet, where wild-type 
rats increased food intake and energy expenditure while FGF-21 knockout mice 
showed no changes in eating behaviour or energy expenditure. Over the course 
of the diet, the FGF-21 knockout mice incurred a significant increase in body and 
fat mass, further implicating that FGF-21 restricts body mass and assists in 
regulating metabolism (Kubicky et al., 2012). It is thought that this regulation is 
part of the liver-brain axis, where fasting has been shown to cause FGF-21 to be 
released from the liver and activates downstream hypothalamic ERK1/2. 
Subsequently, this increases the expression of corticotrophin releasing hormone 
and corticosterone, increasing the rate of gluconeogenesis within the liver (Liang 
et al., 2014). 
Transgenic mice over expressing the thermogenic protein UCP-1, showed an 
increase in the induction of the FGF-21 gene and also had a fivefold increase in 
circulating FGF-21 protein (Keipert et al., 2013). Interestingly, the treatment of 
white adipocytes with the serum of the UCP-1 transgenic mice also caused the 
expression of UCP-1 within the wildtype adipocytes, indicating that FGF-21 is 
likely a cause for morphogenic changes that occur within adipose tissue (Kiepert 
et al., 2013). In support of the findings by Kubicky et al. (2012) and Keipert et al. 
(2013) also described that the UCP-1 transgenic mice also had reduced bone 
growth and smaller overall size, a key indication of the growth restriction that can 
be induced by FGF-21. 
Very little has been studied in terms of the relationship between exercise and 
FGF-21 in animal models. A progressive ramp exercise test for 60 min or until 
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reaching exhaustion caused a significant increase in plasma FGF-21 in mice 
(Kim et al., 2013). There was no significant increase in FGF-21 mRNA in muscle, 
but there was a significant increase in hepatic FGF-21 mRNA. PPAR-α and 
ATF4, known positive regulators of FGF-21, were also elevated in the exercised 
mice. These data indicate that the FFA released during exercise may be the 
cause of the observed increase in plasma FGF-21 because PPAR-α is heavily 
regulated by the presence of free fatty acids (FFA) (Kim et al., 2013). The 
authors also concluded that it is also likely that FGF-21 is not a true myokine, but 
is secreted as a result of lipolysis induced by exercise.  
2.3.3 Human Studies 
FGF-21 in humans appears to behave similarly to the findings in both animal and 
cellular studies. In human subjects with specific mitochondrial myopathies such 
as lacking Iron-Sulfur cross bridges, FGF-21 protein has been reported to be 
circulating at greater concentrations (Crooks et al., 2013). Many of these 
myopathies act at Complex II of the electron transport chain, which is in 
accordance with the findings of Ribas et al. (2012), who used oligomycin to 
inhibit Complex II and induce an FGF-21 response. These studies indicate that 
FGF-21 may be a sensor for the energy availability or productive capabilities of 
the cell.  
A diurnal rhythm of FGF-21 exists, where plasma concentrations peak at 0800h 
and are lowest at 1700h, with a half life of ~two h in humans (Lee et al., 2013; 
Scalzo et al., 2014). A study investigating the effect of ambient temperature on 
the secretion of FGF-21 found cooler temperatures induced a far greater FGF-21 
response and the change in FGF-21 correlated positively with changes in 
glycerol, an indicator of FFA (Lee et al., 2013). Once again these findings 
indicate FGF-21 may be a consequence of FFA circulating in the body, helping 
orchestrate a response to energy substrate availability. Moreover, when 
examining patients with metabolic syndrome, FGF-21 was elevated at rest 
(Bobbert et al., 2013). When adjusted for age, sex, BMI, fasting glucose and 
cholesterol, FGF-21 remained an independent predictor of metabolic syndrome. 
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This knowledge allowed the authors to conclude that FGF-21 may act to 
counterbalance very early pathophysiological conditions such as elevated 
plasma lipids and is thus elevated earlier on in the development of metabolic 
syndrome (Bobbert et al., 2013). In men, it was found that plasma FGF-21 is 
negatively related to cardiorespiratory fitness as defined as peak VO2 (Taniguchi 
et al., 2014). These data support the findings of Scalzo et al. (2014), who found 
that aerobic training caused a reduction in resting FGF-21 concentrations, 
indicating that there may be an inverse relationship between aerobic fitness and 
resting FGF-21 plasma concentrations. Alternatively, FGF-21 and visceral 
adipose were positively related. These results suggest that as visceral fat 
increases within the body and its associated consequential increase of FFA 
within the blood, so will FGF-21(Taniguchi et al., 2014). This relationship may 
serve as the mechanism for the elevated and resistant state of FGF-21 in 
obesity. 
In relation to exercise, FGF-21 is influenced by both the sympathetic activation of 
exercise and muscular contraction. Basal concentrations of FGF-21 are not 
influenced by sympathetic inhibition via administration of clonidine, yet increases 
during hypoxia-induced sympathetic activation and its concurrent increase in 
circulating epinephrine (Scalzo et al., 2014). Any increase in FGF-21 due to 
hypoxia was abrogated with the co-administration of clonidine, solidifying the 
causal nature of sympathetic input for the release of FGF-21. It is likely that 
exercise-induced FGF-21 is highly related to epinephrine and lipolysis because 
sympathetic inhibition does not affect basal FGF-21, yet acute activation of the 
sympathetic system does (Scalzo et al., 2014). Humans undergoing either a 50 
or 80% VO2max treadmill run for 30 min have been observed to induce an 
increase in plasma FGF-21 one hour after the cessation of exercise (Kim et al., 
2013). At one h there was also a significant difference between the 50% and 
80% VO2max tests, indicating a potential dose-response relationship between 
exercise intensity and FGF-21 secretion. Kim et al. (2013) also measured peak 
FFA concentrations, which occurred immediately after exercise. Considering that 
immediate response of FFA and the delayed increases in FGF-21, it is likely that 
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the FFA response of exercise may be the cause of the subsequent release of 
FGF-21. Contrary to these findings, Cuevas-Ramos et al. (2012) found no acute 
changes in plasma FGF-21 concentrations at one and four h after a treadmill 
ramp test producing an energy output of 22 metabolic equivalents (energy 
required as measured by oxygen consumption for resting/basal metabolism) at 
its peak. In the same study conducted in overweight women, aerobic training in 
the form of nine treadmill ramp tests caused resting FGF-21 to increase as well 
as epinephrine and FFA. Considering that the FGF-21 gene is responsive to the 
effect of FFA on the PPAR-α transcription factor, it may be due to increased 
lipolysis and its resulting increase in circulating FFA. It was postulated that FGF-
21 becomes elevated to increase lipid metabolism to prevent any ectopic 
deposition of lipid that may be caused by the increase in FFA post exercise 
(Cuevas-Ramos et al., 2012).  Additional training studies have found that a 
combined aerobic and resistance training program consisting of 45 min of 
aerobic training at 70% of age predicted maximum heart rate and 20 min of 
resistance training caused a 44% reduction in resting plasma FGF-21 after three 
months (Yang et al., 2011). The training was conducted five d per week for 12 wk 
which also resulted in a significant decrease in body mass index, indicating the 
decline in resting FGF-21 may be induced by a loss of body fat (Yang et al., 
2011). A sprint training modality has also been studied where an interval exercise 
program consisting of four-eight, 30 sec, all-out sprints caused a reduction in the 
resting concentration of FGF-21 after nine sessions of training (Scalzo et al., 
2012).  
From the studies outlined above, FGF-21 appears to be a myokine that is an 
early indicator of obesity which can be up regulated by mitochondrial 
abnormalities and is responsive to exercise and exercise training. FGF-21 is 
capable of inducing an oxidative phenotype and is responsible for shifts in 
adipose phenotypes. It is possible that FGF-21 is a response to the adrenergic 
and lipolytic effects of exercise, but these conclusions are currently unclear. The 
relationship between FGF-21 and exercise has not been thoroughly researched 
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and thus focus on this myokine is warranted, specifically in the area of both SIE 
and SIT. 
2.4 Interleukin-15 
Discovered in 1994 by Grabstein et al. and Giri et al., Interleukin-15 (IL-15) is a 
59 amino acid member of the four α-helix family of cytokines. IL-15 was originally 
identified as a T-cell growth factor of the immune system which interacts with 
subunits of the Interleukin-2 receptor (Grabstein et al., 1994). IL-15 was first 
implicated in the function of muscle when it was found to be highly expressed in 
muscle (Grabstein et al., 1994) and when the treatment of IL-15 induced the 
accretion of myosin heavy chain proteins in murine and bovine myocytes (Quinn 
et al., 1995). Based on the findings of these original studies, IL-15 was classified 
as an anabolic growth factor.  
2.4.1 Cell Studies 
Cell studies focusing on the effects of IL-15 have been able to show both an 
anabolic role and the ability to induce an oxidative phenotype in muscle.  In one 
of the original papers recounting the anabolic effects of IL-15, Quinn et al. (2002) 
described the induction of hypertrophy independent of IGF-1 in differentiated 
myotubes from mice. Over-expression of IL-15 in same-cell lineage via retroviral 
injection of the IL-15 gene into the cells resulted in 400-fold greater concentration 
of myosin heavy chain and alpha-actinin accretion. The hypertrophic effect 
occurred without proliferation of myoblasts, indicating a sarcoplasmic 
hypertrophic response. It is important to note that the treatment of IL-15 also 
prevented the degradation of protein within the cultured myotubes, making a 
conclusion related to any increase in protein synthesis difficult.  Furmanczyk and 
Quinn (2003) were able to replicate the previous findings regarding the ability of 
IL-15 to induce the accretion of myosin heavy chain protein within differentiated 
human myotubes and muscle fibres. These data are consistent with both studies 
from myogenic precursor and rodent studies, demonstrating an anabolic effect of 
IL-15. 
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The effect of IL-15 on lipid deposition and oxidation is also pronounced within cell 
studies. By treating murine 3T3-L1 adipocytes with recombinant IL-15, Quinn et 
al. (2005) were able to reduce lipid deposition by more than 50% and stimulate 
the release of adiponectin. These findings prompted the authors to conclude that 
there is a direct modulating effect of IL-15 on the function of adipose tissue and 
there is a communication axis between muscle and fat. Furthermore, O'Connell 
and Pistilli (2015) found that the treatment of muscle cells derived from mice with 
recombinant IL-15 had a distinct and significant increase in PGC-1α and PPAR-γ 
expression and greater mitochondrial density when compared to control cell 
lines. These findings indicate that IL-15 may be able to not only reduce the 
accretion of adipose tissue, but also enhance β-oxidation of circulating lipids in 
skeletal muscle. 
2.4.2 Animal Studies 
The role of IL-15 within animal models has been studied extensively in both rats 
and mice. When compared to wild-type mice, transgenic mice over-expressing 
IL-15 have been described as having both elevated muscle IL-15 protein and 
circulating IL-15 in plasma (Quinn et al., 2013). In a treadmill run to exhaustion, 
the IL-15 transgenic mice ran twice the length of time to fatigue when compared 
to wild type mice and also had a lower amount of visceral adipose tissue. In the 
same study, indirect calorimetry of the IL-15 transgenic mice indicated that the 
over-expression of IL-15 induced a lower RER suggesting the mice utilized a 
greater proportion of fat as primary energy substrate. Alongside the over-
expression of IL-15, there was also increased expression of oxidative regulators 
such as PGC-1α, an increase in the oxidative Myosin Heavy Chain Type I and 
markers of mitochondrial lipid oxidation, indicating an induction of oxidative 
adaptations associated to exercise. In a continuation of the previous study, IL-15 
knockout mice did not show any up-regulation of PGC-1α, SIRT-1 or any other 
pro-oxidative mediators after undergoing a bout of exhaustive exercise running 
(Quinn et al., 2014). Wild type mice exhibiting IL-15 expression also had a much 
longer run time to exhaustion. Injection of recombinant IL-15 into the knockout 
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mice was able to up-regulate the aforementioned oxidative mediators, suggesting 
that many of the oxidative adaptations due to exercise are mediated directly 
though IL-15. 
IL-15 is present in mammalian systems in two forms, one long and one short 
signaling domain peptides. In a study examining the effect of either peptide form 
Quinn et al. (2008) identified the short signal peptide as the most efficient 
endocrine signal and that any functional changes in body composition are due to 
the appropriate signal peptide being secreted into the bloodstream. Elevated IL-
15 resulted in significantly reduced body fat (50% for males, 25% for females) 
and increased bone mineral density. In a group of mice over-expressing the 
efficient short signal IL-15 peptide, there were reduced concentrations of 
common pro-inflammatory cytokines such as IL-6 in groups that were fed a high 
fat diet. In the same study, Quinn et al. (2008) found there was no increase in 
muscle protein synthesis under a milieu of IL-15, but a reduction in protein 
degradation. This suggests that IL-15 may not be an anabolic factor, but an anti-
catabolic factor in-vivo.  
In 2010, Quinn et al. identified that physiological concentrations of IL-15 
decrease with age, but expression of IL-15 mRNA did not. However, the 
expression of the soluble IL-15Rα subunit decreased 5-fold with age and 
correlated significantly with circulating IL-15. Based on these data, Quinn et al. 
(2010) suggested that the α-subunit of IL-15 both influences the secretion of IL-
15 into circulation and the responsiveness of tissues to IL-15. Lastly, in clinical 
populations 12 wk of endurance treadmill running led to an increase in IL-15 
expression in the muscle of diabetic rats and also improved intraperitoneal 
glucose tolerance (Kim et al., 2013). 
2.4.3 Human Studies 
In comparison to the myokines outlined above, IL-15 has not been studied to the 
same extent in humans. However, IL-15 has been evaluated in the context of 
both strength and aerobic training. For strength training, Reichman et al. (2004), 
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trained men three days per week for 10 wk. The subjects performed 13 exercises 
each, containing four sets of six-10 repetitions at their 80% one-rep maximum. 
By studying the effect of different haplotypes for the IL-15 receptor α-subunit, it 
was found that 7.1% of the variability of muscle mass gained from the training 
was due to a single receptor haplotype, the IL-15 short signal peptide. These 
findings are consistent with the findings of Quinn et al. (2008), who found that the 
short signal peptide of IL-15 was most efficient as an endocrine signal in animal 
models. The strength exercise increased plasma IL-15 acutely both before and 
after the 10 wk of training and this effect was still significant when accounting for 
any changes in plasma volume due to exercise. In an acute bout of aerobic 
exercise, lean and obese subjects exercised on a cycle ergometer for 120 min at 
a moderate intensity (55-60% of age predicted maximum heart rate). IL-15 was 
increased two-three fold in both lean and obese subjects, with no difference 
between the groups as defined by body mass (Christiansen et al., 2013). In a 
similar study, 30 min of treadmill running at 70% of age predicted maximal heart 
rate in untrained men induced a significant response with a peak plasma IL-15 
concentration reached 10 min after the cessation of exercise (Tamura et al., 
2011). The authors concluded that the release of IL-15 was due to contraction 
induced stimuli rather than from muscular damage caused by exercise because 
the maximum observed creatine kinase response from the exercise was greatest 
at three h post-exercise, while the IL-15 concentration was reduced to normal 
concentrations at three h.  These findings are critical in defining IL-15 as a true 
myokine being secreted from muscle as a response to contraction, rather than a 
global inflammatory response to exercise stress.  
The change in plasma IL-15 due to aerobic training has also been evaluated. 
Christiansen et al. (2010), found that an exercise intervention consisting of 12 
weeks of tri-weekly aerobic running for ~60 min and an energy expenditure of 
500-600 kJ had no effect on circulating IL-15 (with a  concurrent loss of three kg 
of body fat) in obese subjects. However, the combination of energy restriction 
and exercise (with a loss of 12.1kg of body fat) caused a reduction of 25% of 
plasma IL-15. This suggests that plasma IL-15 may be related to the absolute 
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amount of body fat and in obese individuals and that IL-15 may be chronically 
elevated as a marker of inflammation associated with the obese state. 
However, there are also instances where exercise has been shown to have no 
effect on the concentration of plasma IL-15. In endurance trained athletes, 
Ostrowski et al. (1998) found no change in serum IL-15 after 2.5 h of treadmill 
running at 75% of maximum oxygen consumption. It is likely that in this situation 
the athletes may have had a body fat content that was below a threshold value to 
produce IL-15 as proposed by Christiansen et al. (2010) or due to their training 
status, the stimuli of the running was not great enough to illicit a myokine 
response from the muscle tissue. Neilsen et al. (2007) also demonstrated that 
acute, heavy resistance leg exercise was unable to produce a significant 
increase in plasma IL-15. However, there was an increase in muscle IL-15 
mRNA. These findings allowed the authors to speculate that IL-15 may be 
present as a translationally inactive pool. Interestingly, IL-15 mRNA was 
enhanced in muscle groups dominated by Type II fibres, suggesting that 
activation of these fibres may result in the specific secretion of IL-15. If so, it is 
likely that the intensity of exercise is key to the secretion of IL-15 and very high 
intensity weightlifting or sprinting is most likely to induce the strongest myokine 
response from muscle. 
In summary, IL-15 appears to be a muscle-derived signaling protein that is 
capable of inducing both hypertrophy and oxidative adaptations to exercise. It is 
possible that IL-15 is dependent on the absolute fat content of the body in 
mammalian models and that the beneficial effects of exercise such as increased 
fat oxidation and mitochondrial proliferation are directly mediated through IL-15. 
Although there is a significant amount of data supporting the function of IL-15 in 
animal models, much less research exists in human models. This is particularly 
evident in evaluations of sprint exercise, as no studies currently exist profiling the 
effect of SIE on the secretion of IL-15. 
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3 Methods 
3.1 Participants 
Twelve exercise-trained men started and nine finished this study (n=9, age 23.3 
± 2.4 years, height 177.7 ± 4.9 cm, mass 82.1 ± 11.1 kg, body fat 17.2 ± 8.4%; 
mean ± SD). All subjects were recreationally active and participated in regular 
strength and/or aerobic exercise ~3 d/wk, but did not follow specific training 
programs and were not sprint-trained. Potential participants were excluded if they 
had any known metabolic, musculoskeletal or neurological diseases. In addition, 
participants completed a PAR-Q (Canadian Society for Exercise Physiology, 
2002, Appendix D) and a health information form (Appendix C) to screen out any 
potential contraindications to the exercise. Participants could not have engaged 
in any sprint interval training (SIT) within two months of the beginning of the 
experimental procedures. 
All risks and discomforts were explained fully prior to any testing and all 
participants provided written, informed consent. This study was conducted in the 
Exercise Nutrition Research Laboratory (ENRL) and was approved by the Office 
of Research Ethics at The University of Western Ontario. 
3.2   Preliminary Visits 
Prior to experimental testing, participants were required to visit the ENRL on two 
separate occasions for familiarization to laboratory testing procedures and 
screening/baseline measures. 
On the first visit, participants had their body composition measured and were 
familiarized with the computerized, electromagnetically braked Velotron™ cycle 
ergometer (RacerMate, Inc., Seattle, Washington USA), which was used for all 
cycling tasks throughout the study (maximal oxygen consumption [VO2max] and 
sprint exercise). Previous research confirmed the power accuracy of the 
Velotron™ to be within 3% of the power recorded via a dynamic calibration rig 
during high intensity interval exercise (Abbiss et al., 2009). All individual 
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adjustments made to seat height, seat distance, handle bar height and handle 
bar reach were recorded and used for subsequent tests. Once familiarized, 
participants completed a VO2max test. 
On a subsequent day and not within 48 hours of the completion of the VO2max 
test, participants completed a familiarization of the experimental sprint protocol. 
The protocol was described originally by Burgomaster et al. (2005).  Briefly, 
participants completed a series of four Wingate tests (30 sec max efforts; 
resistance of 9% body mass), with a rest interval of four min separating each 
test. During the resting periods, the load against the Velotron™ flywheel was 
reduced to zero and participants were given the option of either active or passive 
recovery. Each received a three min warm-up on a Monark 874E Erogometer 
(Monark, Inc, Vansbro, Sweden) at an absolute resistance of one kg. After the 
three min warm-up, the participants were then allotted a two-min stretching 
period. During the familiarization session total work output or the area under the 
curve of instantaneous power output was recorded as well as peak power output 
and anaerobic power. The total work output was recorded for each Wingate 
within the familiarization session and added together to represent the total work 
output for the sprint session. 
3.3   Experimental Overview 
Participants underwent two experimental conditions: Sprint Interval Exercise 
(SIE) and Continuous Exercise (CE). Each condition consisted of a five h test 
day in the laboratory. Conditions were conducted via a systemically rotated, 
crossover design and were separated by at least one week. Briefly, the first 
participant was assigned randomly to an experimental condition and thereafter 
treatments were systematically rotated to avoid order or training effects.  Each 
subject completed both conditions (SIE and CE). 
On the eve of testing, participants were provided a standardized high 
carbohydrate pasta meal (two g of carbohydrate∙kg body mass-1) in order to 
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minimize the intra and inter-variability of nutritional status (Jeacocke & Burke, 
2010). Participants consumed the pasta meal between 1700-2000 h with no 
additional carbohydrates besides 250 mL of their preferred pasta sauce. 
On test days, participants reported to the ENRL at 0800 h after a 12 h overnight 
fast having been instructed to not exercise or consume alcohol for 24 h prior to 
testing and no caffeine on the morning of the test day. Participants were given a 
standardized breakfast 0830h (~25 kJ∙kg-1 body mass) which consisted of 10 
kJ∙kg-1 of Dempster’s® Original 100% Whole Wheat Bread (Maple Leaf Foods 
Inc., Toronto, Ontario), 11 kJ∙kg-1 of Kraft® Smooth peanut butter (Kraft Canada 
Inc., Don Mills, Ontario) and 200mL of Tropical Grove Apple Cocktail (Lassonde 
Beverages Canada, Toronto, Canada). 
At 0805 h, a resting venous blood sample was taken directly into a four ml EDTA 
vacutainer. A second  one ml sample was taken by a polyurethane syringe 
directly from the catheter into which it was aliquoted into triplicate 70-microlitre 
hematocrit samples, used to determine any changes in blood plasma 
concentration. This sampling procedure was repeated for all time points at which 
a blood sample was taken. At 0925 h, subjects completed an exercise warm-up 
that was identical to that of the SIE familiarization day. At 0930h subjects 
completed either the SIE session or a work-matched (Joules) CE experimental 
trial. Four more blood and hematocrit samples were taken as follows: five, 30, 90, 
and 180 min after the completion of exercise. At 1115h subjects were fed a 
standardized lunch (~17kJ∙kg-1 body mass), consisting of the same ingredients 
as breakfast. 
3.4   Exercise Protocol 
The aim of the experiment was to conduct a work-matched (per-joule basis) 
comparison of exercise intensity on the effect of plasma myokine accummulation 
between SIE and CE. For this project, exercise intensity is referred to as a 
percentage of measured VO2max. To do this the exercise protocols were designed 
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to have the same total work output. The length of the CE session was thus 
determined by the total work output from the SIE familiarization session or the 
SIE experimental trial in the situation where the systematic rotation of the 
experimental trials determined that the SIE trial was performed first. 
3.4.1 Continuous Exercise Trial 
The intensity of the CE trial was set at a load that would elicit a VO2 response of 
~65% of VO2max because this is a moderate intensity and is common for many 
aerobic exercise training regimes (American College of Sports Medicine. ACSM 
Guidelines for Exercise Testing and Prescription. Whaley MH, ed. 7th ed. 
Philadelphia, PA: Lippincott Williams & Wilkins; 2006). The load of the CE trial in 
kgm∙min-1 was determined using the following equation: 
                      
                         
Note that for this experiment that MET (Metabolic Equivalents) was set to a value 
of 2.6 ml of O2∙kg
-1∙min-1 as it has been shown that the traditional value of 3.5 ml 
of O2∙kg
-1∙min-1 is a significant overestimation and that 2.6 is a more accurate 
value (Byrne et al., 2005, McMurray et al., 2013). Metabolic Equivalents are 
defined as the as energy required for basal/resting metabolism as measured by 
oxygen consumption. The VO2max value was taken from the VO2max test that all 
participants completed during their preliminary visit to the laboratory. 
Once the load for the CE trial was determined in kgm∙min-1, it was converted to 
watts using the equation: 
                      
The length of the CE trial was then calculated using the total work output in 
Joules from either the familiarization trial or the SIE experimental trial, depending 
on the participant’s order of experimental trial rotation. The length of the CE trial 
in sec was determined using the following equation: 
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The CE was then conducted on the Velotron™ cycle ergometer interfaced with 
computer based, interactive Coaching Software (RacerMate Inc, Version 1.15). 
The Coaching Software’s ergometer mode ensured participants maintained the 
prescribed workload irrespective of cadence. Participants were provided with a 
schematic profile of power output throughout the trial as well as real-time 
feedback of time elapsed and time remaining. 
3.4.2 Sprint Interval Exercise Trial 
The SIE trial was conducted as described by Burgomaster et al. (2005), 
consisting of a series of four Wingate tests each separated by four min of 
recovery. The Wingate cycle test is a computerized measure of anaerobic power, 
described originally by Barr-Or and colleagues (1977). Briefly, participants sat on 
the Velotron ergometer and cycled as fast as possible for 30 sec against a 
flywheel resistance set to 9% body mass in kg. Total work output, peak power 
(highest power output over any five sec) and anaerobic power were determined 
using an online data acquisition system (Computrainer, RacerMate Inc, Seattle, 
WA). As explained earlier, the load against the flywheel during the recovery 
periods was set to zero so that the subject’s choice of active recovery would not 
affect the total work output. 
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3.5   Measurements 
3.5.1 Body Composition 
Air displacement plethysmography body volume (BodPod®) and body mass were 
used to determine body density. Participants were required to fast three h prior to 
entering the BodPod®, and to wear approved clothing (compression shorts and 
lycra swim cap) to minimize errors due to air in hair or under clothing. Thoracic 
volume was estimated via a calculation integral to the BodPod® software. In order 
to estimate body composition, the attained body density was imputed into the Siri 
(Siri, 1961) equation 
3.5.2 Aerobic Capacity 
VO2max was determined via a 25 W∙min-1 incremental ramp protocol on a 
Velotron™ cycle ergometer. Briefly, the ramp protocol consisted of a two min 
warm-up at a self-selected wattage followed by an increase to an initial 
resistance of 90-125 W (depending on body mass) with subsequent five W 
increases every 12 sec. Expired gases were collected via a breath-by-breath 
collection system (Sensormedics Vmax 29, Yorba Linda, CA). The greatest value 
achieved over a 30 sec collection period was considered max whenever a 
plateau in VO2 occurred (<50% of the expected increase in oxygen uptake for the 
increased workload) or when two of the following three criterion measures were 
attained (95% of age predicted maximum HR, RER >1.15 [RER = volume of CO2 
produced/volume of O2 consumed] or volitional exhaustion). 
3.5.3 Blood Sampling and Hematocrit 
To determine any changes of plasma myokines concentration, blood samples 
were taken pre-exercise, five, 30, 90 and 180 min post- exercise. All venous 
blood samples were drawn by a certified nurse, who employed standard sterile 
blood handling techniques to prevent infection or contamination. Prior to any 
specimen collection, the participants were debriefed regarding the blood draw 
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process as well as informed of the procedure in place in case of an adverse 
reaction. 
Prior to exercise a 20 gauge indwelling catheter (BD Angiocath™, Becton, 
Dickinson and Company©, New Jersey, USA) was inserted into a vein in the 
antecubital area of either one of the subject’s arms and an IV set three-way 
stopcock (MED-RX®, Benian Inc., Oakville, Canada) was attached. For any of 
the blood samplings, blood was drawn into a four ml BD Vacutainer ® EDTA 
collection tube (Lavender top, Becton, Dickinson and Company©, New Jersey, 
USA), inverted eight times and immediately centrifuged. The vacutainers were 
centrifuged for 10 min at 3000x g at four°C (Allegra™ 21R, Beckman Coulter™, 
California, USA). Plasma obtained was aliquoted into two,  two ml Eppendorf 
tubes (Eppendorf Inc., Mississauga, Ontario) and frozen at -20°C for ~three 
weeks and then transferred to -70°C until later analysis. After the blood samples 
were taken, two ml of 0.9% Injectable Saline USP (Hospira, Montreal, QC, 
Canada) was injected back through the catheter to act as a saline lock to keep 
the catheter patent in between samples. Any remaining saline was drawn off 
from the catheter using a separate BD Luer Lok™ 3ml syringe (Becton, 
Dickinson and Company©, New Jersey, USA) and discarded before any 
Vacutainer samples were taken. 
For hematocrit, an additional one ml of blood was drawn into a BD Luer Lok™ 
one ml syringe (Becton, Dickinson and Company©, New Jersey, USA) and then 
drawn via capillary action into Drummond® Heparinized microcapillary tubes 
(Drummond Scientific Co. Broomall, PA, USA). The microcapillary tubes were 
then sealed at one end by Critoseal® (Oxford Labware®, St. Louis, MO, USA). 
The microcapillary tubes were centrifuged for three min in a Triac™ Hematocrit 
Centrifuge (Clay Adams, Division of Becton, Dickinson and Company©, New 
Jersey, USA). The centrifuged microcapillary tubes were then measured against 
a ruler to determine the Packed Cell Volume (PCV) as a proportion of the total 
volume within the microcapillary tube. The PCV was used to determine any 
changes in plasma volume due to the pressure gradient effects of exercise (Van 
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Beaumont, 1972). Plasma volume may also have been affected by osmotic 
pressure due to the effect of exercise metabolites increasing in concentration 
within the cellular compartment. These two factors were considered when 
analyzing any changes in plasma volume.  
3.5.4 Blood Analysis 
Blood was analyzed and myokines were quantified using commercially available 
Enzyme-Linked Immunosorbent Assay (ELISA) Kits. FGF-21 and IL-15 were 
measured using the Human FGF-21 and IL-15 Quantikine ELISA kits (R&D 
Systems, Minneapolis, Minnesota, USA). Irisin was measured using Phoenix 
Pharmaceuticals Inc. Irisin ELISA assay kit (EK-052-67). 
3.6   Statistical Analysis 
Statistical analyses were conducted using SigmaPlot for Windows (Version 12.0). 
All data were analyzed using a two-way repeated measures ANOVA (condition x 
time). Tukey’s HSD was used for post-hoc analysis to determine any significant 
effects. In order to determine effect sizes, a partial eta-squared analysis was 
conducted. Linear regressions were also performed to determine any association 
between, fat mass, lean mass and the absolute peak concentration of plasma 
myokines. Significance was set at p ≤ 0.05. Data are presented as means ± SD. 
 
 
 
 
   38 
 
 
4 Results 
4.1 Descriptive Statistics 
Of the original 12 participants, three could not finish the entire study. One subject 
withdrew due to an illness unrelated to the study and two others withdrew 
because they relocated away from the London area. Subject 6 was eliminated 
from all analyses because all samples consistently had negative absorbances 
and thus below zero concentrations of myokines. Subject 9 was removed from 
the Irisin analysis due to the fact that its ELISA readings were also all negative 
absorbances. The catheters clotted at the following timepoints and thus no 
samples were obtained: Subject  2 and 11 at 180 min in sprint condition and 
subject 2 and 3 at 180 min in the endurance condtion.  Subject 8 also temporarily 
clotted 5 min post endurance condition. The clot did not remain and thus it was 
the only data point that was lost. 
The training history of the participants was varied. Of the participants three were 
competitive power lifters, one was a trained hockey player, one was a 
competitive ultimate frisbee athlete and four others exercised approximately 
three days per week, but did not follow specific aerobic or resistance training 
programs. It must be noted that only one of the subjects elected to choose active 
recovery while resting between sets of Wingates while performing the sprint 
condition. 
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Table 4.1. Participant characteristics and performance test results 
Values are mean±SD; y = years; kg = kilograms; cm = centimetres; % = percent; 
min = minutes; VO2max = maximal oxygen uptake; J = joules; W = watts  
 
 
Participant 
# 
 
Age 
(years) 
 
Mass 
(kg) 
 
Height 
(cm) 
 
Lean 
Body 
Mass 
(kg) 
 
Fat 
Mass 
(kg) 
 
Body 
Fat 
 (%)  
 
VO2max 
(mL O2 
•kg
-1
 
•min
-1
) 
 
SIE Trial 
Work 
output 
(J) 
 
65% 
VO2max 
(W) 
 
Length 
of CE 
Trial 
(min) 
1 25 90.1 182.0 76.0 14.1 15.6 58.3 81902.2 255 5.41 
2 25 98.2 183.0 69.0 29.2 29.7 42.7 85149.7 184 7.71 
3 22 79.0 178.0 67.2 15.8 20.2 49.7 65882.0 182 6.03 
4 22 89.5 180.5 81.1 8.8 9.8 61.1 91924.8 267 5.74 
6 23 67.6 167.0 62.5 3.6 5.4 56.8 60573.0 185 5.45 
7 22 86.9 175.0 65.1 21.9 25.1 41.8 65640.0 160 7.89 
8 24 83.4 177.0 67.3 16.3 19.5 38.9 64410.2 143 7.52 
9 19 60.0 182.0 56.3 3.1 5.2 52.0 43106.2 147 5.19 
11 28 84.5 174.5 63.6 20.9 24.7 35.1 60409.7 135 7.18 
 
Mean 
 
23.3 
 
 
82.1 
 
 
177.7 
 
 
67.1 
 
 
14.9 
 
17.2 
 
48.5 
 
68777.5 
 
 
184.2 
 
6.55 
 
SD 2.4 
 
11.1 
 
4.9 
 
7.1 
 
8.1 8.4 8.7 13452.7 44.7 1.00 
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4.2 Hematocrit and Hemoconcentration 
There was no significant main effect of time or exercise condition. There was a 
significant interaction effect (exercise condition x time; p= 0.04). Pairwise 
comparisons (Tukey) indicated that PCV was significantly greater at 5 min post-
exercise with SIE condition when compared to CE condition (p<0.001). At 5 min 
post SIE, PCV increased from 46.4 percent to 51.9 percent. The CE condition 
had no significant effect on PCV. Neither exercise condition was significantly 
different at any other time point (Fig 4.1). 
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Figure 4.1. Hematocrit changes after SIE or work-matched CE as denoted 
by Packed Red Blood Cell Volume as percent of total microcapillary tube 
volume. (* = p<0.05) Data are means mean ±SD (n=8). 
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Table 4.2. Percent changes in plasma volume after SIE or work-matched 
CE. 
 
 
 
The change in plasma volume (%ΔPV) was calculated with the following 
equation: 
     
   
          
 
                   
       
 
 
Effect size estimates (ɳ2) indicated that 6% of the variability in hematocrit was 
due to exercise condition and 11% of the variability was due to time. These 
values translate to medium-large effect sizes. 
 
 
 
 
 5 min post 
exercise 
30 min post 
exercise 
90 min post 
exercise 
180 min post 
exercise 
SIE -19.5 2.8 -6.0 2.1 
CE -5.2 3.8 -2.8 4.7 
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4.3 IL-15 
There was no significant main effect of time (p=0.55) or exercise condition 
(p=0.71) on the plasma accummulation of IL-15. There was also no significant 
interaction effect (condition x time, p=0.34) (Fig 4.2). Further, due to a high 
degree of variability within duplicates from the IL-15 ELISA assay, IL-15 was 
excluded from any remaining analysis. 
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Figure 4.2. Change in plasma IL-15 concentration (pg/ml) with SIE or work-
matched CE. Data are presented as a mean± SD, n=8 
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4.4 Irisin 
There was no significant main effect of exercise condition (p=0.18), time (p=0.28) 
or interaction effect (p=0.32) (Fig 4.3).  
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Figure 4.3. Change in plasma Irisin concentration with SIE or work-matched 
CE. Data are presented as means ±SD, n=7.  
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4.4.1 Irisin and Body Composition 
Plasma Irisin concentration correlated significantly with lean body mass at rest 
(Correlation coefficient = 0.78, p=0.001, r2=0.6; Fig 4.4). After exercise, plasma 
Irisin was not correlated to muscle mass at either 5 min post exercise or 180 min 
post exercise. 
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Figure 4.4 Correlation between lean body mass and resting plasma Irisin 
concentration. Correlation coefficient = 0.78, p=0.001, r2=0.6, n=7. 
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Figure 4.5. Correlation between lean body mass and plasma Irisin 5 
minutes post-exercise under either SIE or CE paradigm. Correlation 
coefficient=0.40, p=0.17, r2=0.32, n=7. Subject 8 in the sprint condition is 
missing. 
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Figure 4.6. Correlation between lean body mass and plasma Irisin 180 
minutes post-exercise under either SIE or CE paradigm. Correlation 
coefficient=0.44, p=0.20, r2=0.19, n=5. 
 
4.5 FGF-21 
There was no significant main effect of time or exercise condition. There was a 
significant interaction effect (condition X time), p=0.04). Pairwise comparisons 
(Tukey) indicated mean plasma FGF-21 concentration was elevated significantly 
at 30 min (p<0.001) post-exercise within the sprint interval condition (Fig 4.7). At 
this time point, mean plasma FGF-21 rose from 49.4 ng/ml at rest to 107.64 
ng/ml. Further, at 30 min after exercise, SIE induced a significantly greater 
plasma FGF-21 concentration (p=0.03) vs CE, with a mean difference of 57.2 
ng/ml between SIE and CE. Continuous exercise had no significant effect on the 
accumulation of FGF-21. 
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Figure 7. Change in plasma FGF-21 concentration with SIE or work-
matched CE. All data are presented as mean ±SD. * indicates that the 
concentration of FGF-21 is significantly greater than rest within the sprint 
interval group (p=0.04, p<0.001). # indicates significantly greater 
concentration of plasma FGF-21 for SIE vs CE at 30 min post-exercise 
(p=0.03), n=8. 
Effect size estimates (ɳ2) indicated that 3% of the variability in plasma FGF-21 is 
due to exercise condition, 11% is due to time and 5% due to the interaction effect  
(exercise condition  x time). These translate to small, medium and small effect 
sizes, respectively. 
All correlations between plasma FGF-21 and body fat %, lean body mass or fat 
mass at rest or post-exercise were nonsignificant. 
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5 Discussion 
The primary finding from the present study is that an acute bout of SIE increased 
plasma FGF-21 significantly at 30 min after the cessation of exercise. Further, 
the SIE bout increased plasma FGF-21 significantly at 30 min post-exercise vs 
CE, suggesting a physiological difference in the capacity to induce a systemic 
FGF-21 response between the two exercise modes.  In contrast, there was no 
significant effect of either exercise mode on Irisin or IL-15 plasma concentration. 
However, Irisin was correlated positively with lean body mass at both rest, 
suggesting that total muscle mass may influence systemic Irisin concentrations. 
Interestingly, this relationship was no longer present post-exercise. IL-15 and 
FGF-21 were not significantly correlated to any body composition parameter.  
5.1 IL-15 
This is the first study to examine the effects of SIE on the plasma concentration 
of IL-15 but neither SIE nor CE altered plasma IL-15 concentration significantly. 
However, the results need to be evaluated in context because there was a high 
degree of intra-assay variability in duplicate samples as well as variability 
between subjects. For this reason, it was difficult to make a definitive conclusion 
regarding these data. Some of this variability is likely attributed to sample 
preparation because it appeared that some samples were not uniform in their 
consistency. Learning from this, all FGF-21 and Irisin samples were vortexed, re-
centrifuged and aliquoted after thawing to ensure uniformity. Regardless of these 
sample preparation issues, some comments about the IL-15 data are 
appropriate. Previously published values of plasma IL-15 with endurance 
treadmill running and strength exercise in lean, healthy subjects range from ~1.6-
12.6 pg/ml (Christiansen et al., 2013; Riechman et al., 2004; Tamura et al., 2011) 
and the current data are similar.  Further, compared to the present investigation 
(n=9), the previous studies had larger samples sizes; n=13 (Tamura et al., 2011), 
n=15 (Christiansen et al., 2013), especially the Reichman et al. (2004) study 
(n=76).  Consequently, the present observed IL-15 response may have been 
nonsignificant due to variability, i.e., a Type II error. Moreover, although the 
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current study was designed to isolate the effect of exercise intensity on the 
plasma concentration of IL-15, the absence of an increase may suggest that a 
minimal exercise duration is necessary for an IL-15 response. Including rest 
periods, the present SIE protocol took a total of 14 min (exercise was only 2 min) 
and the work-matched CE took only 6.5 min.   This is shorter than previously 
published studies that reported IL-15 increases.  For example, Tamura et al., 
2011 reported significant mean increases from 1.71 pg/ml to 1.95 pg/ml after 30 
min of running at 70% of age-predicted heart rate maximum. Although the 
intensity of the CE trial in the current study was comparable (65% VO2max) to 
Tamura et al. (2001), the total time of exercise was ~5 times less. This same 
situation applies to the study by Christiansen et al. (2013), where subjects ran 
continuously at a moderate intensity for 60-75 min. Also, using high-intensity 
muscular contractions (strength exercise for more than one h duration), 
Riechman et al. (2004) observed a significant increase in plasma IL-15. Based 
on these findings, it is possible that the secretion of IL-15 is dependent on some 
interaction between total exercise time (or volume) and intensity. Clearly, more 
study is needed to sort this out. 
5.2 Irisin 
No significant effect of exercise on the plasma concentration of Irisin was 
observed in the current study. From the literature, baseline Irisin concentrations 
range from ~90-140 ngl/ml (Huh et al., 2012, Huh et al., 2014, Tsuchiya et al., 
2014, Daskalopoulou et al., 2014). With the present study the mean baseline and 
post-exercise values of Irisin concentration were approximately 10-fold less than 
published values. Due to the uniformity of this phenomenon and the fact that the 
standards from the ELISA kit produced values as expected, it may be that the 
low observed Irisin concentrations are the result of an error within the sampling 
process. Huh et al. (2012) point out Irisin sample concentrations are unaffected 
by freeze-thaw cycles, when stored at -80°C. The current Irisin samples were 
stored at -20°C initially for ~three weeks before being transferred to -70 C 
storage so, it is possible that some protein degradation occurred, thus reducing 
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the concentration of Irisin and perhaps affecting the sensitivity of the experiment 
to any changes that may have occurred, regardless of the exercise condition. 
Hecksteden et al. (2013) found that Irisin has a degradation rate of 0.184 ng∙ml-
1∙day-1 when stored at -20°C. Therefore, although this may have contributed to 
some of degradation within our samples, it is unlikely that it is the entire cause for 
the low Irisin concentrations because if the degradation rate found by 
Hecksteden et al.(2013) occurred, it would have taken 62 wk to produce the 
values found within our samples.  Obviously, something else was involved. Both 
SIE and high intensity exercise in general have been reported to produce 16-
35% increases in plasma Irisin within 5 min of the completion of exercise (Huh et 
al., 2012, Huh et al., 2014, Daskalopoulou et al., 2014). In the current study, SIE 
caused no change in plasma Irisin concentration 5 min post exercise, but did 
show a 28% increase 3 h post-exercise.  Although nonsignificant, this percent 
increase in plasma Irisin is similar to previous studies.   
Tsuchiya et al. (2014), have suggested that there may be a decrease in plasma 
Irisin immediately after high intensity exercise (20 min treadmill running at 80% 
VO2max) followed by an increase in plasma Irisin 3 h post-exercise. The present 
increase observed with CE at three h post exercise was smaller (12%) when 
compared to SIE.  As with IL-15 the present results were quite variable and with 
the small sample size it is possible that the lack of significant change was the 
result of a Type II error. 
A significant increase in plasma Irisin 5 min post exercise was anticipated. 
However, no such increase in plasma Irisin was observed in either exercise 
condition. These findings are surprising in that the work load studied is similar or 
greater to those used in the literature. For example Huh et al. (2012), 
implemented three sets of two, 80 metre sprints with each set separated by 20 
min of rest and reported a 16% increase in plasma Irisin. A second study 
investigating six, 50 metre maximal swim sprints with a mean completion time of 
~32 sec observed a 30% increase in plasma Irisin, 5 min post exercise (Huh et 
al., 2014). The current SIE involved a similar exercise time (four, 30 sec exercise 
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bouts) as Huh et al. (2014) but two less exercise bouts. Consequently, it is 
possible that our sprinting protocol was below the required exercise duration to 
induce an Irisin response, i.e., two additional sets of sprints may have causes a 
significant change. The rest/recovery intervals within the Huh et al. (2014) were 
similar (5 min) to those of the current study, thus diminishing the likelihood that 
the current results were due to rest/recovery interval differences. It is also 
possible that the mode of exercise played an important role in the lack of an Irisin 
response. Both Huh et al. studies (Huh et al., 2012, 2014), used full-body 
exercises in the form of track sprinting and freestyle swimming sprints. These 
exercises likely engaged a larger muscle mass in comparison to our study which 
was mainly quadriceps dependent (cycling). Further, the convective properties of 
water may have influenced these results. Huh et al. (2014) used swimming 
sprints and the convective ability of water to draw heat away from the bodies of 
the subjects may have artificially lowered body temperature. In conjunction with 
FGF-21, Irisin has been found to induce non-shivering thermogenesis through 
the uncoupling of the electron transport chain (Lee et al., 2014). So with cooler 
body temperatures induced by water, Irisin may have been released into the 
bloodstream to contribute to non-shivering thermogenesis. Regardless, the 
results of the current study appear to show a reduced effect of exercise on 
plasma Irisin vs the literature. 
The observation that that resting Irisin is correlated to lean body mass is of 
particular interest. These findings are consistent with a previous study which 
found biceps circumference as a measure of lean body mass to be correlated 
positively with resting plasma Irisin (Huh et al., 2012). Together these data 
suggest that a major source of plasma Irisin is skeletal muscle. However, it 
cannot be determined that the source of Irisin is skeletal muscle alone because it 
could also originate from the motor nerve tissue permeating through skeletal 
muscle as suggested by Aydin et al. (2014). If correct, this could have 
contributed to the observed reduced Irisin response in the current study because 
less motor units would have been active during the cycling exercise used and 
thus less nerve tissue was active to contribute to an Irisin response. 
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Paradoxically, the correlation between circulating Irisin and lean body mass was 
no longer present post-exercise. It is possible that the production of Irisin may be 
a result of the basal metabolism of skeletal muscle. Therefore at rest, Irisin would 
be produced equally among all muscle tissue and be correlated to lean body 
mass. When exercising, it is likely that ATP is diverted away from homeostatic 
functions such as myokine production and shunted for the purpose of muscle 
fibre contraction. Thus, the linear relationship would be abrogated, producing the 
results that were observed within our current study. 
The training history of the subject may have played a role in the results. Many of 
the subjects regularly participated in strength and resistance training and it could 
be thus assumed that they would have had a larger proportion of Type IIx muscle 
fibres. It has been shown that in untrained individuals, plasma Irisin is related to 
the proportion of Type I fibres (Ellefsen et al., 2014). However, the same study 
showed that the relationship between Irisin and Type I fibres was no longer 
present after 12 weeks of whole body resistance training. It is likely that the 
participants within the current study had approximately the same amount of 
resistance training profiled by Ellefsen et al., and thus plasma Irisin would not be 
related to their fibre type composition. Physical fitness appears to have no effect 
on the acute accumulation of Irisin or other myokines. Huh et al, 2014, found that 
there was no difference in the acute accumulation of Irisin after a treadmill run to 
exhaustion in relation to participant VO2max. This suggests that the results of the 
current study was not dependent on the cardiorespiratory fitness of the subjects. 
Although the literature suggests this conclusion, it is imperative that for further 
studies a precise training history would be taken and that subjects would be 
matched on training history and VO2max.  
5.3 FGF-21 
The present study has shown that there is a significant effect of SIE on the 
plasma concentration of FGF-21. At both 5 and 30 min post exercise, there was 
a significant increase in plasma FGF-21 concentrations. Further, at 30 min post 
exercise, the SIE response was significantly greater than CE. These findings 
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suggest that there is a physiological difference between SIE and CE relative to 
plasma FGF-21 accumulation. Finally, current baseline measures of FGF-21 
compare favourably to published values at approximately the same daily time 
(10:00h, 50-60 ng/ml) (Lee et al., 2013). Peak FGF-21 concentrations occur at 
0800h and reach a minimum at 1700h (Lee et al., 2013). Following this trend, the 
natural variation of plasma FGF-21 would be decreasing during the sampling 
period of the present study. Therefore, it is likely that the increase in plasma 
FGF-21 concentration was due to exercise and not the natural diurnal rhythm of 
FGF-21. 
Moreover, it is likely that there is a dose-response relationship between exercise 
intensity and the subsequent plasma concentration of FGF-21 because SIE 
caused a significantly greater FGF-21 response in comparison to CE. These 
findings are in congruence with those of Kim et al. (2013), who found that 30 min 
of treadmill running at 80% VO2max induced a 60% greater FGF-21 response than 
30 min at 50% VO2max. It is therefore plausible that as length and intensity of 
exercise increases, so too will the plasma concentration of FGF-21. 
It is important to rule out any possible effect of reduced plasma volume that may 
be the underlying cause for the significant increase in plasma FGF-21 
concentration within the sprint interval condition. There was a significant increase 
in hematocrit and thus a significant decrease in plasma volume within the sprint 
condition 5 min post-exercise. This is caused by the increase in intramuscular 
pressure due to exercise, causing an increase in mean arterial pressure and thus 
an efflux of fluid from the plasma compartment. Another important factor is the 
increase of osmotic pressure from the muscular compartment due to increased 
exercise metabolites within the muscle that had not reached equilibrium with the 
plasma. The change in plasma volume at 5 min post-sprint therefore influenced 
the concentration of FGF-21 and after correction for these plasma volume 
changes, no significant difference was found. 30 min-post exercise, there was no 
significant change in hematocrit or plasma volume, thus the increase in FGF-21 
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concentration at this time point is likely not attributable to any change in plasma 
volume. 
Some data suggest that cardiorespiratory fitness can play a role in the 
determination of FGF-21 concentration, i.e., resting FGF-21 has been inversely 
related to VO2max (Taniguchi et al., 2014). Therefore it is possible that the wide 
range of cardiorespiratory fitness of the present subjects (35-61.1 ml∙O2
-1∙kg-
1∙min-1) may have limited the absolute responses to exercise within each subject. 
This range of responses may have therefore confounded any other mean 
observable changes in FGF-21 concentration.   
Since there was an observed increase in FGF-21 concentration with SIE, it is of 
interest to speculate about possible mechanisms behind this response to 
exercise. First, it is possible that FGF-21 is produced by contracting muscle, but 
the observed increase in plasma FGF-21 concentration could also be an indirect 
response to exercise. For example, Scalzo et al. (2014) showed that baseline 
FGF-21 concentration is not determined by basal sympathetic input, but will 
increase in response to hypoxia-induced sympathetic activation. When the 
hypoxia-induced sympathetic activation was inhibited by the administration of 
clonidine (a central acting adrenergic agonist), the subsequent increase in FGF-
21 concentration was also eliminated (Scalzo et al., 2014). Therefore it appears 
that sympathetic activation is necessary for the accumulation of FGF-21 and that 
sympathetic activation during exercise may be a primary cause for the 
accumulation of FGF-21. Second, Kim et al. (2013) have shown that peak FGF-
21 concentration is observed ~one h post-exercise and ~one h after peak blood 
FFA is reached. Cuevas-Ramos et al. (2012) have proposed that because the 
PPAR-α transcription factor (which plays a significant role in the regulation of the 
FGF-21 gene) is stimulated by FFA, it is lipolysis that causes the induction of 
FGF-21. If so, this could explain the latency (30 min -one h) in which peak FGF-
21 concentrations are reached. Therefore, it may be that the increase in FGF-21 
was due to the sympathetic activation and associated lipolysis of SIE. FGF-21 is 
highly expressed within the liver (Bae et al., 2014; Nishimura et al., 2000), as well 
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as its co-receptor, β-Klotho. As theorized by Cuevas-Ramos et al. (2012), FGF-
21 is produced by the liver in response to increasing FFA to increase lipid 
metabolism in order to prevent the ectopic deposition of lipids that had been 
liberated as a result of exercise. Therefore from these findings, it is possible to 
suggest that FGF-21 can be used as a surrogate measure for sympathetic 
activation and lipolysis associated to exercise. This theory may also help explain 
the dramatic fat loss associated with regular SIT, in that a greater amount of 
lipolysis may occur within each acute bout of training, as exemplified by relative 
increases in circulating FFA.  
5.4 Limitations 
There a few important limitations to this study that need to be addressed. As 
mentioned, the study itself was relatively underpowered. Consequently, it is 
possible with a sample size of 9 that the statistical analyses were subjected to 
potential Type II errors. The present ELISA results also proved to be highly 
variable.  This needs to be eliminated.  Attempts were made to minimize the 
errors made in the IL-15 sample preparation with the Irisin and FGF-21 analyses, 
but additional steps for sample preparation should be taken including: 1) pre-
chilling EDTA tubes with ice baths before taking blood samples and 2) consistent 
freezer storage at -80°C. In the present study, some samples were stored at -
20°C and then transferred to the colder freezers. It is possible that there was a 
degree of protein degradation due to storage temperature that may have affected 
the absolute values of myokine concentrations within our samples. These 
limitations make definitive conclusions regarding the acute effect of exercise 
mode on plasma myokine accumulation difficult.  
Further, into the future, it is important to test the effect of SIT to determine 
whether any training adaptations alter the acute response of FGF-21 to SIE. It is 
possible that the observed changes within the current study may be altered with 
training and this needs to be determined.    
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5.5 Future Directions 
Based on the current findings, further studies on the effect of SIE on the 
accumulation of FGF-21, Irisin, and IL-15 in plasma are warranted due to the 
errors made with sampling. Second, it is necessary to determine if the acute SIE 
is abrogated by the administration of clonidine to determine if the secretion of 
FGF-21 is dependent entirely on the sympathetic activation of exercise. Third, 
FFA could also be measured with SIE to document any relationship between 
circulating FFA and plasma FGF-21. Fourth, it is would be of interest to 
determine whether PPAR-α is up-regulated by acute SIE to determine the 
molecular regulators and mechanisms behind the production of FGF-21 after 
exercise. Fifth, SIT studies should be completed to determine if the acute effect 
of SIE on plasma FGF-21 is altered with training. Sixth, assessing different SIE 
modalities, including running, swimming, cycling and strength exercise would be 
of interest to determine how plasma myokine concentration is affected by 
exercise modality.  Seventh, increasing work volume studies should be 
investigated because if IL-15 and Irisin are dependent on a threshold volume of 
exercise, it might not have been met with the current study. This could be 
accomplished through additional sprint sets or alternatively, using a pre-
determined CE protocol i.e. (15 min at 60% VO2max) to then determine the 
~number of sprints to match work outputs. It is also important to match the 
subjects based on training history to determine if there is any effect on the acute 
accumulation of myokines. This way any variability based on fibre type 
composition may be eliminated. Eighth, assessing the capture of myokines 
against a known concentration. This would require spiking a blood sample with a 
known concentration and processing it with the exact same aliquoting and 
storage procedure. This will help determine to what extent the yield from the 
blood sampling was accurate for our results. Finally, muscle biopsies might be 
utilized to determine if the change in IL-15 is localized more directly within the 
muscle tissue for paracrine/autocrine signaling, rather than serving as an 
endocrine molecule. This may apply to myokine protein production or perhaps 
the induction of its respective mRNA. It is not possible to conclude that the total 
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change in plasma myokine concentration is attributable to production alone 
because plasma concentration is a net result of production and degradation. 
Microdialysis may be one technique that could be used to determine the 
production of myokines. Acting similarly to a capillary bed, microdialysis probes 
are capable of measuring solutes flowing directly out of a tissue. The 
implementation of this technique would allow for the determination of myokine 
production directly from the tissue without interaction with the plasma. 
5.6 Summary and Conclusion 
Nine young, physically active men completed four, 30 sec sprints and a work-
matched continuous interval bout at 65% VO2max on an electromagnetically 
braked cycle ergometer. Changes in plasma concentration of three myokines 
were measured via ELISA assays: IL-15, Irisin and FGF-21. In contrast to the 
experimental hypothesis, IL-15 and Irisin showed little effect of either exercise 
treatment; however, plasma FGF-21 was elevated significantly with SIE. 
Specifically, at 5 (p=0.039) and 30 min (p<0.001) post-SIE, plasma FGF-21 was 
increased. At 30 min post exercise, this observed FGF-21 increase was greater 
vs the work-matched CE condition (p=0.03). 
These results suggest that SIE elicits a physiologically different response to 
exercise when compared to CE at least with FGF-21. They also indicate that per 
joule of work, sprint interval exercise is capable of generating a significantly 
greater systemic FGF-21 response. Moreover, elevated FGF-21 may indicate 
that there is a greater fatty acid release during SIE because FGF-21 may be a 
surrogate measure of sympathetic activation during exercise. Therefore, it is 
possible that the fat loss associated with SIT may be related directly to the 
amount of FFA generated during and following each acute sprint interval training 
session.  
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